12:00 AM
 | 
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Recombinant botulism vaccine: Phase II data

A double-blind, placebo-controlled, U.S. Phase II trial in 440 healthy volunteers showed that intramuscular 0.5 mL doses of DynPort's recombinant botulism vaccine given on days 0, 28 and 182 or days 0, 56 and 182 produced maximum immune responses to both botulinum neurotoxin serotypes A...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >